Literature DB >> 29026974

Pheochromocytoma as a frequent false-positive in adrenal washout CT: A systematic review and meta-analysis.

Sungmin Woo1, Chong Hyun Suh2,3, Sang Youn Kim1, Jeong Yeon Cho1,4, Seung Hyup Kim5,6.   

Abstract

OBJECTIVE: To evaluate the proportion of pheochromocytomas meeting the criteria for adenoma on adrenal washout CT and the diagnostic performance of adrenal washout CT for differentiating adenoma from pheochromocytoma.
METHODS: MEDLINE and EMBASE were searched to 28 March 2017. We included studies that used adrenal washout CT for characterisation of pheochromocytomas. Two independent reviewers assessed the methodological quality using Quality Assessment of Diagnostic Accuracy Studies-2. Proportions were pooled using an inverse variance method for calculating weights (random-effects). Sensitivity and specificity were pooled using hierarchical logistic regression modelling and plotted in a hierarchical summary receiver-operating-characteristics (HSROC) plot.
RESULTS: Ten studies (114 pheochromocytomas) were included. The pooled proportion of pheochromocytomas meeting the criteria for adenomas was 35 % (95 % CI 20-51). For eight studies providing information on diagnostic performance, the pooled sensitivity and specificity for differentiating adenoma from pheochromocytoma were 0.97 (95 % CI 0.93-0.99) and 0.67 (95 % CI 0.44-0.84), respectively. The area under the HSROC curve was 0.97 (95 % CI 0.95-0.98).
CONCLUSIONS: There was a non-negligible proportion of pheochromocytomas meeting the criteria for adenoma on adrenal washout CT. Although overall diagnostic performance was excellent for differentiating adenoma from pheochromocytoma, specificity was relatively low. KEY POINTS: • Non-negligible proportion of pheochromocytomas can be mistaken for adenoma. • Adrenal washout CT showed good sensitivity (97%) but relatively low specificity (67%). • Findings other than washout percentage should be used when diagnosing pheochromocytomas.

Entities:  

Keywords:  Adrenal adenoma; Adrenal washout CT; Meta-analysis; Percentage washout; Pheochromocytoma

Mesh:

Year:  2017        PMID: 29026974     DOI: 10.1007/s00330-017-5076-5

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  30 in total

Review 1.  Adrenal imaging: why, when, what, and how? Part 1. Why and when to image?

Authors:  Giles W L Boland
Journal:  AJR Am J Roentgenol       Date:  2010-12       Impact factor: 3.959

Review 2.  Adrenal imaging: why, when, what, and how? Part 2. What technique?

Authors:  Giles W L Boland
Journal:  AJR Am J Roentgenol       Date:  2011-01       Impact factor: 3.959

Review 3.  Incidental adrenal lesions: principles, techniques, and algorithms for imaging characterization.

Authors:  Giles W L Boland; Michael A Blake; Peter F Hahn; William W Mayo-Smith
Journal:  Radiology       Date:  2008-12       Impact factor: 11.105

4.  Adrenal adenomas and nonadenomas: assessment of washout at delayed contrast-enhanced CT.

Authors:  D H Szolar; F H Kammerhuber
Journal:  Radiology       Date:  1998-05       Impact factor: 11.105

5.  Incidental adrenal lesions: accuracy of characterization with contrast-enhanced washout multidetector CT--10-minute delayed imaging protocol revisited in a large patient cohort.

Authors:  Minal J Sangwaiya; Giles W L Boland; Carmel G Cronin; Michael A Blake; Elkan F Halpern; Peter F Hahn
Journal:  Radiology       Date:  2010-08       Impact factor: 11.105

6.  Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delayed contrast-enhanced CT.

Authors:  Dieter H Szolar; Melvyn Korobkin; Pia Reittner; Andrea Berghold; Thomas Bauernhofer; Harald Trummer; Helmut Schoellnast; Klaus W Preidler; Hellmuth Samonigg
Journal:  Radiology       Date:  2005-02       Impact factor: 11.105

7.  Adenoma characterization: adrenal protocol with dual-energy CT.

Authors:  Yi Kyung Kim; Byung Kwan Park; Chan Kyo Kim; Sung Yoon Park
Journal:  Radiology       Date:  2013-01-17       Impact factor: 11.105

8.  Can established CT attenuation and washout criteria for adrenal adenoma accurately exclude pheochromocytoma?

Authors:  Jeet Patel; Matthew S Davenport; Richard H Cohan; Elaine M Caoili
Journal:  AJR Am J Roentgenol       Date:  2013-07       Impact factor: 3.959

9.  QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies.

Authors:  Penny F Whiting; Anne W S Rutjes; Marie E Westwood; Susan Mallett; Jonathan J Deeks; Johannes B Reitsma; Mariska M G Leeflang; Jonathan A C Sterne; Patrick M M Bossuyt
Journal:  Ann Intern Med       Date:  2011-10-18       Impact factor: 25.391

Review 10.  Systematic Review and Meta-Analysis of Studies Evaluating Diagnostic Test Accuracy: A Practical Review for Clinical Researchers-Part I. General Guidance and Tips.

Authors:  Kyung Won Kim; Juneyoung Lee; Sang Hyun Choi; Jimi Huh; Seong Ho Park
Journal:  Korean J Radiol       Date:  2015-10-26       Impact factor: 3.500

View more
  11 in total

1.  Accuracy of focal cystic appearance within adrenal nodules on contrast-enhanced CT to distinguish pheochromocytoma and malignant adrenal tumors from adenomas.

Authors:  Michael T Corwin; Ana S Mitchell; Machelle Wilson; Michael J Campbell; Ghaneh Fananapazir; Thomas W Loehfelm
Journal:  Abdom Radiol (NY)       Date:  2021-01-08

Review 2.  Adrenal pheochromocytoma: is it all or the tip of the iceberg?

Authors:  Ke Wang; Guanglei Tang; Yang Peng; Chang Li; Wenhao Fu; Ruixi Li; Jian Guan
Journal:  Jpn J Radiol       Date:  2021-09-21       Impact factor: 2.374

3.  Diagnostic value of the relative enhancement ratio of the portal venous phase to unenhanced CT in the identification of lipid-poor adrenal tumors.

Authors:  Shengze Jin; Huangqi Zhang; Wenting Pan; Jiawen Yang; Binhao Zhang; Xue Dong; Xin Li; Xiuli Wu; Wenbin Ji
Journal:  Abdom Radiol (NY)       Date:  2022-07-01

4.  Characteristic CT features of pheochromocytomas - probability model calculation tool based on a multicentric study.

Authors:  Filip Ctvrtlik; Zbynek Tudos; Paulina Szasz; Zuzana Sedlackova; Igor Hartmann; Jan Schovanek; Zdenek Frysak; Iva Macova; Tomas Zelinka; Milan Hora; Eva Kocova; Jaroslav Pacovsky; Michal Krsek; Viera Lehotska; Emilia Mojtova; Josef Molnar; Vladimir Vanek; Karel Pacak; Jan Baxa
Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub       Date:  2019-09-23       Impact factor: 1.245

5.  Distinguishing pheochromocytoma from adrenal adenoma by using modified computed tomography criteria.

Authors:  Sohi Kang; Young Lyun Oh; Sung Yoon Park
Journal:  Abdom Radiol (NY)       Date:  2020-09-20

Review 6.  [Pheochromocytoma and paraganglioma : Importance of diagnostic imaging].

Authors:  W G Kunz; C J Auernhammer; S Nölting; T Pfluger; J Ricke; C C Cyran
Journal:  Radiologe       Date:  2019-11       Impact factor: 0.635

7.  Differentiation of lipid-poor adenoma from pheochromocytoma on biphasic contrast-enhanced CT.

Authors:  Yong-Yu An; Guang-Zhao Yang; Bin Lin; Nan Zhang; Hong-Tao Hou; Fang-Mei Zhu; Feng-Juan Tian; Jian Wang
Journal:  Abdom Radiol (NY)       Date:  2021-05-25

8.  Diagnostic Value of Unenhanced CT Attenuation and CT Histogram Analysis in Differential Diagnosis of Adrenal Tumors.

Authors:  Paulína Szász; Petr Kučera; Filip Čtvrtlík; Kateřina Langová; Igor Hartmann; Zbyněk Tüdös
Journal:  Medicina (Kaunas)       Date:  2020-11-09       Impact factor: 2.430

Review 9.  Adrenal Mass Characterization in the Era of Quantitative Imaging: State of the Art.

Authors:  Maxime Barat; Anne-Ségolène Cottereau; Sébastien Gaujoux; Florence Tenenbaum; Mathilde Sibony; Jérôme Bertherat; Rossella Libé; Martin Gaillard; Anne Jouinot; Guillaume Assié; Christine Hoeffel; Philippe Soyer; Anthony Dohan
Journal:  Cancers (Basel)       Date:  2022-01-23       Impact factor: 6.639

10.  Computed Tomography-Based Machine Learning Differentiates Adrenal Pheochromocytoma From Lipid-Poor Adenoma.

Authors:  Haipeng Liu; Xiao Guan; Beibei Xu; Feiyue Zeng; Changyong Chen; Hong Ling Yin; Xiaoping Yi; Yousong Peng; Bihong T Chen
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-21       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.